# US 2013/0296319 A1 · N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296319 A1
- Document ID: US20130296319A1
- Status: Published application
- Kind: A1
- Application number: 13/939,450
- Filed: 2013-07-11
- Published: 2013-11-07
- Earliest claimed: 2009-11-10
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Scott William Bagley; David Andrew Griffith; Daniel Wei-Shung Kung
- Web page: https://patentgrep.com/patent/US20130296319A1

## CPC

- C07D 471/10: Spiro-condensed systems
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/12: Antihypertensives
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

## Claims

### Claim 1

A compound of Formula (I)
wherein
R1 is (C1-C6)alkyl, (C3-C7)cycloalkyl, tetrahydrofuranyl or oxetanyl; wherein said (C1-C6)alkyl is optionally substituted with (C1-C3)alkoxy, phenyl, or tetrahydrofuranyl;
R2 is hydrogen, halo, (C1-C3)alkyl, or cyano;
R3 are each independently hydrogen or (C1-C3)alkyl;
R4 is naphthyl optionally substituted with one to four substituents independently selected from (C1-C3)alkyl, (C1-C3)alkoxy, halo, amino, (C1-C3)alkylamino, di(C1-C3)alkylamino, hydroxy, cyano, amido, phenyl, 5 to 6 membered heteroaryl or 5 to 6 membered heterocyclyl; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein R1 is (C1-C6)alkyl, (C3-C7)cycloalkyl, or tetrahydrofuranyl; and R2 is hydrogen or methyl.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein R1 is isopropyl or t-butyl; R2 is hydrogen; and each R3 is hydrogen.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, diluent or carrier.
